Bone Abstracts

see PP292....

IGF1 is an osteo-anabolic factor that stimulates osteogenic precursor cell differentiation. IGF1 is produced in bone in response to mechanical stimulation, but also in mechanically-stimulated muscle cells. IGF1 enhances the rate of mRNA translation in muscle cells via activation of the PI3K/AKT/mTOR pathway, thereby increasing in muscle mass. Therefore we hypothesized that IGF1 not just enhances osteogenic differentiation of precursors, but also stimulates protein syn...

Osteoporosis is common in rheumatoid arthritis (RA). Since osteoblasts express receptors for CXCL8 and CCL20, which are produced by inflammatory cells around the inflamed joints in RA, we hypothesized that CXCL8 and CCL20 contribute to osteoporosis in RA by affecting osteoblast proliferation, differentiation, and osteoblast-osteoclast communication.Primary human osteoblasts were cultured±CXCL8 (2–200 pg/ml) and CCL20 (5–500 pg/ml) for 14 d...

see P487....

see P75....

Delayed fracture healing is frequently experienced in patients with systemic inflammation such as during rheumatoid arthritis (RA). The reasons for this are diverse, but could also be caused by inflammatory cytokines and/or growth factors in serum from patients with active disease. We hypothesized that serum from patients with active RA contains circulating inflammatory factors that inhibit differentiation of osteochondrogenic precursors.Serum was obtain...

Breastfeeding women resorb trabecular bone to supply much of the calcium content of milk. Few studies have examined the speed and extent of BMD recovery after weaning, or the factors that predict a greater post-lactation increase in BMD. We hypothesize that weight-bearing, nutrition, hormones, and other factors facilitate bone formation after lactation.The aims of the Factors Affecting Bone Formation After Breastfeeding Pilot Study (FABB-Pilot) were to d...

An increasing number of biomaterials are in development, seeking to mimic the natural cascade of events during fracture repair. However, these biomaterials need to be rigorously tested prior to clinical application. In vitro testing lacks the physiological environment, while in vivo studies do not always predict the patient response. Here we hypothesize that the chorioallantoic membrane (CAM) assay can be used to culture human living bone and we aim to examin...

Objectives: Burosumab, a monoclonal antibody that therapeutically targets the underlying elevated levels of fibroblast growth factor 23 (FGF23) in X-linked hypophosphatemia (XLH), is now available to children out of trial conditions. Our objective was to describe the effect of burosumab on quality of life, functionality and pain in a clinical setting.Methods: Questionnaire tools were completed at baseline, 6 and 9 months for 9 children with XLH starting ...

Burosumab, a monoclonal antibody targeting fibroblast growth factor 23, is now available for clinical use in children with X-linked hypophosphatemia (XLH). We aimed to explore the effects of burosumab in children with XLH in a clinical setting, considering: a) Biochemistry b) Growth c) Lower limb deformity (LLD) d) Radiology e) Motor function<p class="abstext"...